SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) — BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in September.
Details of the company’s participation are as follows:
Links for live webcasts and replays, if available, will be available in the on the “Investors” page of the BBOT website. Replays will be available on the website for at least 90 days following the event.
About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.
BBOT Contacts:
Investor Contact:
Uneek Mehra, Chief Financial Officer
BBOT
Investors@BBOTx.com
Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com
Landover, Maryland, February 6, 2026- The UA Sprinkler Fitters Local 669 Joint Apprenticeship and Training…
Regional program delivers double-digit sales growth, improved service performance, and expanded diagnostic access across Latin…
Four new products available now to put full diagnostics in the palm of technician's handsSPARKS,…
Global leaders, entrepreneurs and innovators will converge across the Tampa Medical & Research District and…
IPSWICH, Mass., Feb. 6, 2026 /PRNewswire/ -- New England Biolabs (NEB ®) will present several…
PLEASANTON, Calif., Feb. 6, 2026 /PRNewswire/ -- Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"),…